Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer

Joo Hyuk Sohn, Yong Tai Kim, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Byung Soo Kim, Chang Ok Suh, Gwi Eon Kim, Woo Ick Jang, Hyun Cheol Chung
2003 Cancer research and treatment : official journal of Korean Cancer Association  
Purpose: A sing le institute trial of com bination chem otherapy, w ith paclitaxel and cisplatin, in patients w ith m etastatic breast cancer, having failed previous com bination chem otherapy, w as perform ed. Materials and Methods: Patients w ere only eligible for this study if there disease had progressed, follow ing treatm ent w ith previous chem otherapy, in either an adjuvant or a m etastatic setting. Paclitaxel 175 m g/m 2 w as adm inistered as a 3-hour continuous infusion on day 1, and
more » ... isplatin 80 m g/m 2 was adm inistered for 2 hours on day 2, w ith adequate hydration. This w as repeated every 3 w eeks, and continued until one of the follow ing events occurred: disease prog ression, unacceptable adverse effect or treatm ent refusal by the patient. Intercurrent palliative radiotherapy, or concurrent horm onal therapy, w as perm itted, depending on each patient's status. A ll the endpoints w ere evaluated under the principle of intention to treat analysis. Results: A total of 24 patients entered the study, and 18 had at least one m easurable lesion, but 6 did not. The objective response rate of the 18 patients was 50% (9/18). Two were complete responses and seven show ed partial responses. The m edian response duration, progression free and overall survival w ere 5.3 m onths (range, 4 18), 6 m onths (95% CI, 5 7) and 12 m onths (95% CI, 7 17), respectively. 67% of the planned dose w as adm inistered. O ut of a total 135 cycles adm inistered, about 20% of cycles show ed grade 3 or 4 leukopenia and 7% show ed grade 3 throm bocytopenia. Tw o patients suffered from pneum onia, and one experienced neutropenic fever. M ucositis, greater than grade 3, existed in three cases. N o treatm ent related deaths w ere reported. Conclusion: The com bination chem otherapy, w ith paclitaxel and cisplatin, w as active in the treatm ent of m etastatic breast cancer patients having failed previous chem otherapy. (Cancer Research and Treatment 2003;35:267-273)
doi:10.4143/crt.2003.35.3.267 pmid:26680946 fatcat:5sxvhzaxzjh4pml7e6kf66y7qy